Amicus Therapeutics (FOLD) Prelim. FY Revenue Tops Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
January 9, 2023 7:00 AM ESTSignificant Growth in Demand with More Than 2,000 People Living with Fabry Disease on Galafold by End of 2022
2022 Full Year Revenue of ~$329M, Representing 16% YoY Growth at CER
Continued Double-Digit Growth in Galafold Revenue of 12-17% at CER Expected in 2023
Multiple Approvals and Launches Expected in 2023 for AT-GAA in Pompe Disease
On-Track to Achieve non-GAAP Profitability in 2H2023
PHILADELPHIA, Jan. 09, 2023 (GLOBE NEWSWIRE) --... More
